Islet cell killing mediated by natural killer cells and T-lymphocytes in diabetes-prone (DP) and diabetic BB rats has been described, but other killing mechanisms may also be involved. Histopathologic studies suggest that macrophages are the first immune cells to infiltrate islets. To determine if macrophages are the first cells mediating islet damage, macrophagemediated cytotoxicity was evaluated in BB rats of different ages. Splenic macrophages isolated from DP rats at 33,100,120, and 140 days of age showed no enhanced islet killing compared with diabetes-resistant rats. Killing at diabetes onset (121 ± 14 days) was markedly increased (43 ± 9.3%) compared with agematched diabetes-resistant controls (19 ± 8.3%, P < .001). Islet inflammation was monitored at all time points. At 120 and 140 days of age, 9 of 11 (82%) DP rats had insulitis, and cytotoxicity was increased in 6 of 11 (55%) rats, which is similar to the number of DP rats that progress to diabetes. At 100 days, 3 of 6 (50%) DP rats again showed diabetic levels of killing, even in the absence of insulitis. These data indicate that 1) islet inflammation is dissociated from clinical diabetes onset, 2) splenic macrophages may have islet-killing potential before islet inflammation, 3) macrophage-mediated islet killing is elevated in all animals immediately after diabetes onset, and 4) macrophages, in addition to natural killer cells and T-lymphocytes, are responsible for cell-mediated islet destruction and thus are candidates for the first cellular effector to result in islet killing. Diabetes 38:1329-31,1989
M
acrophages are thought to be active in the pathogenesis of diabetes in both BB rats and NOD mice. Thus, diabetes onset can be prevented by in vivo treatment with silica, which interferes with macrophage function (1, 2) . Islet phagocytosis by macrophages can also occur in BB rats (3, 4) . Histopathologic time-sequence data indicate that macrophages are the first major inflammatory cell population to invade BB rat islets before B-lymphocytes, T-lymphocytes, or natural killer (NK) cells and disease onset (4) (5) (6) (7) (8) . The exact role that macrophages and other cell types have in the islets is unclear, but it is assumed that at least immune activation and cytolysis may occur. Activated peritoneal macrophages from nondiabetic Wistar rats have recently been reported to kill islet and certain xenogeneic tumor cells (9) . For cytolysis, T-lymphocytes and NK cells are described to be cytotoxic to BB islet cells before and after the onset of clinical diabetes (10, 11) . Because macrophages appear early in diabetes pathogenesis, in vitro killing assays were developed to assess whether macrophages are associated with cytolysis and diabetes in BB rats.
RESEARCH DESIGN AND METHODS
Diabetic, diabetes prone (DP), and diabetes resistant (DR) male Wistar BB rats {RT1 U ) were kindly provided by Dr. Pierre Thibert (Univ. of Ottawa, Ottawa). The frequency of diabetes is 30-50% between 100 and 140 days of age. Rats were defined as diabetic if urine glucose was >0.25% (Tes-Tape, Lilly, Indianapolis, IN) and fasting blood glucose was >200 mg/dl. Diabetic rats treated with protamine zinc insulin were studied within 7 days of diagnosis, and intraperitoneal (5 mg/100 g body wt) pentobarbital sodium anesthesia was used.
Splenic mononuclear cells were isolated as previously described (12) . These cells were phenotyped by an indirectimmunofluorescence assay with mouse anti-rat monoclonal antibodies (supernatants, Accurate Chemical and Scientifica, Westbury, NY) OX41, W3/13, OX19, and W3/25 as previously described (10, 11) . In brief, aliquots of 1-5 x 10 5 cells from individual rats were incubated with monoclonal antibodies at a 1:4 dilution. Fluorescein isothiocyanate
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(FITC)-conjugated goat anti-mouse IgG with low cross-reactivity to rat IgG (Caltag, San Francisco, CA) was used at a 1:20 dilution. Cells were assessed with a fluorescence-activated cell-sorter analyzer (Coulter EPICS). Background fluorescence was estimated by incubating cells with FITC-conjugated goat anti-mouse IgG only, and this revealed < 1 % fluorescent cells. FACS analyses confirmed marked decreases in the percentage of splenic T-lymphocytes in the DP strain. In DR, DP, and diabetic rats, splenic T-lymphocytes were 51 ± 2, 33 ± 10, and 11 ± 4% with W3/25, 68 ± 4, 48 ± 11, and 19 ± 6% with W3/13, and 74 ± 2, 32 ± 12 and 12 ± 4% with 0X19 (n > 4), respectively.
Macrophage separation was performed with a standard method (13) . In brief, heat-inactivated fetal calf serum (FCS) was added to plastic petri dishes and incubated overnight at 4°C, after which 50 x 10 6 spleen cells were incubated at 37°C for 15 min. After incubation, nonadherent cells were washed away. Adherent cells were removed from the dishes by incubation at 4°C with Hanks' balanced salt solution containing 0.2% EDTA (EDTA buffer) and 5% FCS. Macrophages were washed and adjusted to 2 x 10 6 cells/ml for the cytotoxicity assay or phenotyping. Cell viability assessed by trypan blue exclusion was >95%. To determine the enrichment of macrophages isolated from BB rat spleens, FACS analysis was performed with monoclonal antibody 0X41. These results indicate that 15 ± 1% 0X41 + cells in splenic mononuclear populations were enriched to 89 ± 5% after plastic adherence (n = 6).
Rat islet target cells from BB and inbred Lewis (RTV) rats were isolated as previously described (14) . In brief, individual islets were dispersed into a single-cell suspension with DNAse (200 |xg/ml, Sigma, St. Louis, MO) in Swim's lowCa 2+ medium (Gibco, Grand Island, NY) containing 1 mM EGTA (Sigma) and 1% bovine serum albumin. The dispersed cells were incubated with 51 Cr (100 |xl sodium chromate, 1 mCi/ml, Amersham, Arlington Heights, IL) at 37°C for 45 min. Spontaneous release was 24 ± 3.8%, and viability was >90% by trypan blue exclusion. An IEC-18 rat ileal epithelial cell line and the GH 3 rat pituitary cell line were used as target-cell controls; spontaneous 51 Cr release was 34.9 and 23.7%, respectively (15, 16) .
The islet cell cytotoxicity assay was performed as previously described in detail (14, 17) . In brief, Dulbecco's minimal essential medium, 10% FCS, 5000 51 Cr-labeled islet target cells, and splenic mononuclear or macrophage-effector cells were added to triplicate 400-fxl polyethylene tubes. Target-to-effector ratios were 1:20 for mononuclear cells and 1:40 for macrophages. Multiple target/effector ratios were evaluated from 1:5 to 1:40 (data not shown). Incubations were performed for 16 h at 37°C in a 5% CO 2 /95% humidified air atmosphere. After incubation, the supernatants were assessed for radioactivity. Maximal release (Triton X-100) was 100% for all target cells. Percentage of specific cytotoxicity was calculated as previously described (14) .
The splenic lobe and body of the pancreas were excised and fixed in Bouin's solution. Sections were stained with hematoxylin and eosin, and morphological lesions were classified (masked) as previously described (5) .
All data are means ± SE. Data were compared by Student's t test.
RESULTS
DR and nondiabetic DP animals were studied for splenic mononuclear cell-mediated islet cytotoxicity at 120 days of age. These results showed similar cytolytic levels at 13 ± 3.4 and 12 ± 1.6% (n = 6). DR and nondiabetic DP rats were evaluated at 30, 100, 120, and 140 days of age for macrophage-mediated islet cell killing ( Fig. 1/4 ). Diabetic rats were evaluated at 121 ± 14 days of age. DR rats had slightly decreased mean killing levels over the age range evaluated, whereas nondiabetic DP rats at different ages had stable levels of islet killing. This divergence resulted in 60 _ A the DP rats having a trend toward more islet cytotoxicity than the DR rats by 140 days of age (NS). Diabetic animals had markedly increased mean levels of cytotoxicity compared with DR (P < .001) or DP (P < .01) rats at either 120 or 140 days of age. The specificity of diabetic splenic macrophagemediated rat islet cell killing was evaluated with inbred Lewis {RTV) islet cells as a major histocompatibility-specificity control and rat gastrointestinal and pituitary cells as tissuespecificity controls. Lewis target cells were lysed similar to DR target cells (56 ± 2.7 vs. 58 ± 6.0%, respectively, n = 4, NS). Macrophage-mediated rat gastrointestinal target cell lysis was 9.2 ± 6.2%, and GH 3 target-cell lysis was 22.6 ± 8.3% {n = 4, P < .001 vs. DR or Lewis islet target cells).
Because it is unclear which DP rats will progress to diabetes, histologic examinations of the islets from all animals were performed to determine if islet inflammation was related to macrophage-mediated islet cell killing. A dissociation of islet inflammation and macrophage-mediated islet killing was observed (Fig. 16) . At 120 and 140 days of age, 9 of 11 (82%) DP rats had islet inflammation, whereas 6 of 11 (55%) DP rats showed macrophage-mediated islet killing in the range of diabetic rats. Furthermore, 3 of 6 (50%) DP rats at 100 days of age also had increased macrophage-mediated islet killing even in the absence of islet inflammation. In the Ottawa colony of BB rats evaluated, 40-50% of DP rats develop clinical diabetes.
DISCUSSION
This study describes a new effector cell in the BB diabetic rat model capable of killing pancreatic islet cells. These data confirm that the inflammatory process in the islets of BB rats is distinct from the development of clinical diabetes and extend the data by showing that islet killing mediated by macrophages from the spleen is a relatively early event; i.e., killing may precede macrophage infiltration of islets.
The killing of pancreatic islet cells in the BB rat model is complicated, because several potential cellular killing mechanisms exist, including T-lymphocytes and NK cells (10, 11) . Our data expand this list to include macrophages. Recent studies also show macrophage-mediated islet killing in nondiabetic Wistar rats, but similar levels of killing were also observed with xenogeneic tumor cells (9) . In the latter study, intraperitoneal injections of Corynebacterium parvum were used to exogenously activate peritoneal macrophages. This result emphasizes the importance of studying such killing in the diabetes model with allogeneic nonislet tumor cells as specificity controls in endogenously activated macrophages. To determine the relationship of islet cytotoxicity to diabetes onset, we used a kinetic cytolytic and histologic model. Our data show that enhanced macrophage-mediated islet killing in some DP rats may occur before onset of diabetes, whereas after onset of diabetes, virtually all rats have increased islet cytotoxicity and inflammation. The number of DP animals showing increased islet killing by macrophages at 120 and 140 days of age (55%) contrasts with the presence of islet inflammation in 82% of the same nondiabetic animals. Data at 100 days indicate that macrophages capable of killing islets may be present even before islet in-NAGY AND ASSOCIATED flammation in 50% of the animals studied, suggesting that macrophage islet killing is not the result of islet necrosis. These data at 100, 120, and 140 days of age imply that macrophage-mediated islet killing may be present only in animals that will develop diabetes, because there is a 40-50% rate of DP animals progressing to diabetes. Furthermore, macrophages may require separate signals for islet infiltration or homing and the cytolytic process, because levels of cytolysis in the diabetic range can precede homing or islet infiltration. The kinetic model used in this study should be a valuable design for evaluation of other immune parameters and their relation to spontaneous diabetes onset.
